HALO · Transaction Mar 9, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · HALO
+0.21% · +$0.2200 · Vol 204.9K
Live · updated 10:22:51 ET
Halozyme Therapeutics Inc
Biotechnology
$103.22
Veridion Score
BETAHIGH CONF · 6/6 factorsMon Aug 17 · last completed session · daily score · 16h old · HALO
MethodologyHALO
Halozyme Therapeutics Inc
Mon Aug 17 · last completed session · daily score · 16h old
STRONG
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
78/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · daily score · 16h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is HALO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Halozyme Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2004
Employees
423
Country
US
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$102.95
Day high
$103.94
Day low
$102.39
Previous close
$103.00
52W high
$103.94
-0.69% from high
52W low
$61.63
98% of range
Market cap
$11.2B
P/E
17.55×
EPS
$5.88
Beta
0.25
Shares out
113.5M
Volume
204.9K
0.09× rel vol
Avg volume
2.2M
VWAP
$103.27
Price history computed in-house
1W
+0.58%
1M
+32.66%
3M
+49.64%
1Y
+49.68%
YTD
+53.37%
SMA 50 $80.19 · above
SMA 200 $71.44 · above
52W position 98%
HALO overview
Related filings and maps
Public disclosures
Congress activity in HALO
Official filing ↗
Gilbert CisnerosSell
HALO · Transaction Mar 24, 2025 · Filed Apr 7, 2025 · $1,001 to $15,000
Halozyme Therapeutics, Inc. - Common Stock · Transaction Sep 9, 2024 · Filed Oct 3, 2024 · $1,001 to $15,000
Daniel GoldmanSell
HALO · Transaction Jul 12, 2023 · Filed Aug 13, 2023 · $15,001 to $50,000
Halozyme Therapeutics, Inc. · Transaction Dec 6, 2022 · Filed Jan 13, 2023 · $1,001 to $15,000
Federal contracts
HALO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HALO in this window.
Lobbying spend
HALO lobbying filings, year to date.
Registered lobbying filings matched to Halozyme Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for HALO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for HALO.
Options
Sovereign unlock shows live options positioning for HALO.